Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Neoplasms 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Cisplatin 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Specimen Handling 10Paclitaxel 6Platinum 5Cyclophosphamide 51,2-diaminocyclohexaneplatinum II citrate 5fludarabine 4durvalumab 4cemiplimab 4Radiotherapy, Intensity-Modulated 4Radiotherapy 3Pemetrexed 3Oxaliplatin 3Nivolumab 3Fluorouracil 3Cetuximab 3Carboplatin 3Biopsy 3poly ICLC 2fludarabine phosphate 2cabozantinib 2atezolizumab 2Radiation 2Ipilimumab 2Interviews as Topic 2Heavy Ion Radiotherapy 2Gemcitabine 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma × VMBP protocol × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡